Triplet Drug Therapy Shows Promise in Urothelial Cancer
A Phase 1b trial reports an 81% response rate for a new three-drug combination in untreated metastatic patients.
Updated on Oct. 23, 2026 in Cancer
Live Poll
Do you trust that new drug combinations for metastatic cancer are effectively improving patient survival?
Researchers presented findings from a Phase 1b clinical trial evaluating a drug triplet of sacituzumab govitecan, enfortumab vedotin, and zimberelimab for untreated metastatic urothelial cancer. The combination demonstrated an 81% objective response rate among the 21 patients studied.
Why it matters
This study aims to assess whether combining multiple antibody-drug conjugates and immunotherapy can improve clinical outcomes for patients with metastatic disease. The findings provide early evidence that this triplet regimen is tolerable and potentially effective, supporting further investigation into this approach for urothelial carcinoma.
The trial reported a median progression-free survival of 19.3 months and a median response duration of 16.7 months. Grade 3 or higher treatment-related adverse effects occurred in 52% of the cohort, with no reported treatment-related deaths.
The players
ESMO Congress
This is an annual international medical event held in Madrid, Spain, that gathers oncology professionals to share research and clinical trial advancements.
University of Chicago
This is an academic research institution that serves as the base for the medical investigators who led this clinical trial.
The details
Patients in the study received sacituzumab govitecan and enfortumab vedotin on days 1 and 8 of each 21-day cycle, alongside 360 mg of zimberelimab on day 1. Among the 21 participants, 3 achieved a complete response and 14 recorded a partial response.
Timeline
July 24, 2026 was the data cutoff date for the trial interim results.
October 23, 2026 marked the presentation of the findings at the ESMO Congress.
The Big Picture
This research contributes to the ongoing development of antibody-drug conjugate immunotherapy combinations in oncological medicine. It shifts the paradigm by testing whether a triplet regimen can outperform existing standards of care for metastatic urothelial carcinoma.
The results suggest a potentially powerful new treatment option for patients facing untreated metastatic urothelial cancer. While encouraging, the findings are limited to an early-phase trial, meaning patients should consult with specialists regarding current standard therapies.
The takeaway
This triplet therapy demonstrates a high initial response rate in early testing for metastatic urothelial cancer patients. Future research will likely focus on confirming these efficacy results in larger, more diverse patient populations.
Further reading
For more information on the latest research in this field, visit the Cancer section.
Live Poll
Do you trust that new drug combinations for metastatic cancer are effectively improving patient survival?
